Dedicated to providing innovative research based products of the highest quality for animals and humans.

News & Events

Envision leadership in the Pharmateutical & Animal Healthcare Markets, through advanced product innovation and strategic alliance

News & Events

The Efficacy of Multi-Strain Probiotics as Adjunct Therapy for Dengue Hemorrhagic Fever Grade II in Children Admitted At a Tertiary Government Hospital: A Randomized Controlled Trial

Date: September 04, 2010

With more than one-third of the world’s population living in areas at risk for transmission, dengue infection is a leading cause of illness and death in the tropics and subtropics.  As many as 100 million people are infected yearly.  Dengue outbreaks in urban areas infested with Aedes aegypti may be explosive; up to 70-80% of the population may be involved.  Most disease occurs in older children and in adults.  The World Health Organization says some 2.5 billion people, two-fifths of the world’s population is now at risk from dengue
and estimates that there may be 50 million cases of dengue infection worldwide this year.  The disease is now endemic in more than 100 countries.
This study aims to determine the efficacy of multi-strain Probiotics (Protexin) as an adjunct therapy in Dengue Hemorrhagic Fever Grade II in children aged 5-17 years old admitted at a tertiary government hospital from January-September 2009.
This is a prospective, randomized controlled, open label clinical trial, involving forty (40) patients.  Twenty (20) patients were assigned in Group A (control group) and twenty (20) patients were assigned in Group B (Protexin group).  The T-test Mann Whitney U test, Fisher Exact test, Chi square test was used to compare different variables.  Patients in Group B (Protexin Group) were given Protexin OD for 9 months.
A total of forty (40) patients were involved in this study.   Patients given Protexin showed a significant difference (p-value of .0002) on the second day with the disappearance of abdominal pain among most of the patients from the Probiotic Group and on the third day, 100% of the patients in the Probiotic group had complete resolution of abdominal pain versus the control group, which showed persistent abdominal pain.  A proportion of subjects with vomiting on the second hospital day were lower in the Probiotic group versus the control group and on the third hospital day none of the subjects showed any signs of vomiting.  5% of the patients in the control group manifested body malaise as compared to none in the Probiotic group. There was also a trend for a smaller decrease in platelet count and earlier return of mean platelet counts to above 100 in the Probiotic Group during the fourth and fifth hospital day.  Although the platelet count of the Control group was greater than 100 on the fifth hospital day, the increase was less compared to that of the Probiotic group. All patients improved clinically and were discharged after a mean of four hospital days.  Although those in
the control group had a slightly longer duration of hospitalization.
There was a significant resolution in abdominal pain in the Probiotic Group (Protexin).  Although there was an earlier resolution of vomiting and an earlier increase in platelet count achieved in the Probiotic group (Protexin) as compared to that of the control group.

Connect with Us

Prebiotech on Facebook Prebiotech on Twitter Prebiotech on LinkedIn Prebiotech on YouTube Prebiotech on Google+

Copyright © 2024. Prebiotech Health Care.
All rights reserved